3 Apparel Manufacturer and Exporter, Domestic Pharmaceutical Leader and Consumer Electricals Maker Stocks With a Strong Future Roadmap: Pearl Global Industries, Mankind Pharma and V-Guard Industries
- November 5, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Pearl Global Industries, Mankind Pharma and V-Guard Industries: ROE of 11.7% to 19.0% and FY22 to FY26 revenue CAGR of 14.3% to 16.5%. Prices as of 4 Nov 2026.
Quick Answer
The three garment, drug and consumer electricals stocks to watch are Pearl Global Industries, Mankind Pharma and V-Guard Industries. Their return on equity ranges from 11.7% to 19.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.3% to 16.5%. Pearl Global Industries leads on both return on equity at 19.0% and revenue growth at 16.5% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
Garment, drug and consumer electricals stocks offer a focused view of a sector where demand keeps widening. Pearl Global Industries, Mankind Pharma and V-Guard Industries cover an apparel manufacturer and exporter, a domestic pharmaceutical leader and a consumer electricals maker.
This list covers three garment, drug and consumer electricals stocks with complete current figures: Pearl Global Industries, Mankind Pharma and V-Guard Industries. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Garment, Drug and Consumer Electricals Stocks?
Garment, drug and consumer electricals stocks are listed companies that make garments for global brands, sell medicines through a large field force in India, and produce voltage stabilisers, fans, wires and water heaters for homes. Their earnings depend on export orders, prescriptions and household spending.
Garment, Drug and Consumer Electricals Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Pearl Global Industries | 1,319.9 | 11,806 | 38.9 | 35.2 | 19.0 | 0.65 |
| Mankind Pharma | 2,537.9 | 93,014 | 45.0 | 36.0 | 11.7 | 0.39 |
| V-Guard Industries | 292.95 | 12,446 | 34.1 | 43.9 | 13.0 | 0.07 |
On valuation, V-Guard Industries trades at a P/E below the industry P/E, while Pearl Global Industries and Mankind Pharma trade above it, which reflects the growth the market already expects. Readers comparing garment, drug and consumer electricals stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in garment, drug and consumer electricals stocks can use the coming numbers to test whether growth is holding.
Why Do Garment, Drug and Consumer Electricals Stocks Have a Strong Roadmap in India?
Garment, drug and consumer electricals stocks have a strong roadmap in India because steady global apparel sourcing, rising chronic care medicine use and growing household electrical needs keep widening the market for these companies.
- Garment exports. Global brands diversify sourcing.
- Pharma. Chronic care medicine use keeps rising.
- Home electricals. Households add fans, heaters and wiring.
Why Pearl Global Industries Features Among These Garment, Drug and Consumer Electricals Stocks
Among the garment, drug and consumer electricals stocks on this list, Pearl Global Industries is a Gurugram-based apparel manufacturer and exporter that makes garments for leading international brands from factories in India, Bangladesh, Vietnam and Indonesia.
The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2.
Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%. Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore.
Roadmap: The company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.
What to watch: Watch order inflow from global brands and the ramp-up of newer factories.
Why Mankind Pharma Features Among These Garment, Drug and Consumer Electricals Stocks
Among the apparel, pharma and consumer shares on this list, Mankind Pharma is one of India’s largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.
Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%.
In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.
Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
What to watch: Watch the market share in chronic therapies and the integration of acquired brands.
Why V-Guard Industries Features Among These Garment, Drug and Consumer Electricals Stocks
Among the three companies on this list, V-Guard Industries is a Kochi-based consumer electricals company that makes voltage stabilisers, inverters, water heaters, fans, kitchen appliances, wires and cables, and solar water heaters.
In the June 2026 quarter, revenue grew 23.9% year on year to Rs 1,822 crore, while net profit rose 76.4% to Rs 130 crore. Revenue rose from Rs 3,511 crore in FY22 to Rs 5,989 crore in FY26, a compound annual growth rate of 14.3%.
Net profit grew from Rs 228 crore in FY22 to Rs 308 crore in FY26, which works out to a compound annual growth rate of 7.8%. The company has a return on equity of 13.0%, a debt to equity ratio of 0.07 and a market capitalisation of Rs 12,446 crore. The stock trades at a P/E of 34.1, below the industry P/E of 43.9.
Roadmap: The company is widening its distribution beyond South India and growing newer categories such as kitchen appliances and cables. Strong brand recall and a growing dealer network support sales across its product basket.
What to watch: Check growth outside South India and the contribution of newer product categories.
Pearl Global Industries vs Mankind Pharma vs V-Guard Industries on Key Financials
The table below sets the three garment, drug and consumer electricals stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Pearl Global Industries | 2,747 | 5,062 | 16.5% | 270 | 5.3% |
| Mankind Pharma | 7,978 | 14,636 | 16.4% | 1,938 | 13.2% |
| V-Guard Industries | 3,511 | 5,989 | 14.3% | 308 | 5.1% |
Pearl Global Industries posts the highest return on equity in this group at 19.0%. Mankind Pharma has the largest FY26 revenue at Rs 14,636 crore, and Pearl Global Industries shows the fastest revenue growth with a 16.5% compound annual rate. A useful habit with garment, drug and consumer electricals stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several apparel export, domestic drug and stabiliser stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Pearl Global Industries | 1,239 | 1,539 | 24.2% |
| Mankind Pharma | 3,650 | 4,076 | 11.7% |
| V-Guard Industries | 1,471 | 1,822 | 23.9% |
Key Risks to Check Before Investing in Garment, Drug and Consumer Electricals Stocks
Every theme carries risks that deserve a check before any decision. For these garment, drug and consumer electricals stocks, the main points are: Long-term apparel, pharma and consumer shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Currency moves. Export earnings move with the rupee.
- Consumer spending. Sales follow festivals, incomes and consumer mood.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter garment, drug and consumer electricals stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Garment, Drug and Consumer Electricals Stocks
Garment, drug and consumer electricals stocks reward patient research into demand, execution and financial strength. Pearl Global Industries, Mankind Pharma and V-Guard Industries each have a clear plan to grow. Based on the 4 November 2026 close, Pearl Global Industries trades at Rs 1,319.9, Mankind Pharma at Rs 2,537.9 and V-Guard Industries at Rs 292.95. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these garment, drug and consumer electricals stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track garment, drug and consumer electricals stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are garment, drug and consumer electricals stocks?
Ans. Garment, drug and consumer electricals stocks are listed companies that make garments for global brands, sell medicines through a large field force in India, and produce voltage stabilisers, fans, wires and water heaters for homes. Their earnings depend on export orders, prescriptions and household spending. This list looks at three of them, Pearl Global Industries, Mankind Pharma and V-Guard Industries, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which garment, drug and consumer electricals stocks are covered in this list?
Ans. This list covers Pearl Global Industries, Mankind Pharma and V-Guard Industries. Based on the 4 November 2026 close, Pearl Global Industries traded at Rs 1,319.9, Mankind Pharma at Rs 2,537.9 and V-Guard Industries at Rs 292.95. Their return on equity ranges from 11.7% to 19.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.3% to 16.5%.
Why do garment, drug and consumer electricals stocks have a strong future roadmap in India?
Ans. Garment, drug and consumer electricals stocks have a strong roadmap in India because steady global apparel sourcing, rising chronic care medicine use and growing household electrical needs keep widening the market for these companies. The main drivers are as follows. Garment exports. Global brands diversify sourcing. Pharma. Chronic care medicine use keeps rising. Home electricals. Households add fans, heaters and wiring. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Pearl Global Industries performed financially?
Ans. Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%. Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore. The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2. Looking ahead, the company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.
How has Mankind Pharma performed financially?
Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
How has V-Guard Industries performed financially?
Ans. Revenue rose from Rs 3,511 crore in FY22 to Rs 5,989 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 228 crore in FY22 to Rs 308 crore in FY26, which works out to a compound annual growth rate of 7.8%. In the June 2026 quarter, revenue grew 23.9% year on year to Rs 1,822 crore, while net profit rose 76.4% to Rs 130 crore. The company has a return on equity of 13.0%, a debt to equity ratio of 0.07 and a market capitalisation of Rs 12,446 crore. The stock trades at a P/E of 34.1, below the industry P/E of 43.9. Looking ahead, the company is widening its distribution beyond South India and growing newer categories such as kitchen appliances and cables. Strong brand recall and a growing dealer network support sales across its product basket.
What risks should investors check before buying garment, drug and consumer electricals stocks?
Ans. Investors should check a few risks before buying garment, drug and consumer electricals stocks. Currency moves. Export earnings move with the rupee. Consumer spending. Sales follow festivals, incomes and consumer mood. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of garment, drug and consumer electricals stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.